Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · DEF 14A

Scienture Holdings, Inc.

SCNXNASDAQEQUITYCurrent

SEC Filing

Filed Sep 18, 2026Accepted Sep 18, 2026, 4:05 PM EDTCIK 1382574Accession 0001493152-26-043340
Share

Company context

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, including Scienture, LLC is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information xplease visit www.scienture.com.

Current securities

Recent company filings

  1. Regulation FD DisclosureSep 14, 2026
  2. PRE 14A filingSep 8, 2026
  3. Results of Operations and Financial ConditionAug 20, 2026
  4. 10-Q filingAug 13, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsMay 29, 2026

As-filed source

Primary evidence